Su Dr. ssa Daniela Vivenza

TITOLI DI STUDIO

–  Specializzazione in Patologia Clinica presso l’Università degli Studi di Torino.

– Abilitazione all’esercizio della professione di Biologo per l’iscrizione alla sezione A dell’albo professionale, presso l’Università degli Studi di Torino.

– Dottorato di Ricerca in Medicina Molecolare (XVII ciclo) presso l’Università degli Studi del Piemonte Orientale “A. Avogadro” di Novara.

– Corso di Perfezionamento in “Diagnostica Molecolare in Medicina” presso l’Università degli Studi di Torino.

–  Laurea in Scienze Biologiche presso l’Università degli Studi di Torino.

ESPERIENZA LAVORATIVA

Marzo1998 – Ottobre 2001: Tirocinante post-laurea (per abilitazione professionale secondo il D.P.R. N.980, 28 ottobre 1982) e borsista presso il Laboratorio della Clinica di Medicina Interna, Dipartimento di Scienze Mediche, Università del Piemonte Orientale “Amedeo Avogadro” di Novara.

Novembre 2001 – Novembre 2005: Borsista per il conseguimento del Dottorato di Ricerca in Medicina Molecolare (XVII ciclo) presso il Laboratorio della Clinica Pediatrica, Dipartimento di Scienze Mediche, Università del Piemonte Orientale “Amedeo Avogadro” di Novara).

Novembre 2006 – Marzo 2008: Assegnista di Ricerca presso il laboratorio della Clinica Pediatrica, Dipartimento di Scienze Mediche, Università del Piemonte Orientale “Amedeo Avogadro” di Novara.

Aprile 2008 – Giugno 2009: Borsista presso il Dipartimento di Medicina ed Oncologia Sperimentale, Sezione di Biochimica, Università degli Studi di Torino e presso il Centro di Neuro-Bio-Oncologia di Vercelli.

Luglio 2009 – Febbraio 2014: Ricercatrice ARCO presso il Laboratorio di Genetica Oncologica ed Oncologia Translazionale del Dipartimento di Oncologia, Ospedale Santa Croce e Carle di Cuneo.

Da Marzo 2014 = Borsista della Fondazione Veronesi “Post-Doctoral Fellowship 12 mesi” presso il Laboratorio di Genetica Oncologica ed Oncologia Translazionale del Dipartimento di Oncologia, Ospedale Santa Croce e Carle di Cuneo.

Pubblicazioni

testimonial-1

Vivenza D, Lo Nigro C, Denaro N, Fortunato M, Monteverde M, Tonissi F, Lattanzio L, Astesana V, Gloghini A, Volpi CC, Russi E, Merlano MC.

Int J Biol Markers. 2016 Mar 22:0. doi: 10.5301/jbm.5000193. [Epub ahead of print]

testimonial-2

 Lattanzio L, Milano G, Monteverde M, Tonissi F, Vivenza D, Merlano M, Lo Nigro C.

Anticancer Drugs. 2016 Mar 15. [Epub ahead of print]

testimonial-3

Lo Nigro C, Ricci V, Vivenza D, Monteverde M, Strola G, Lucio F, Tonissi F, Miraglio E, Granetto C, Fortunato M, Merlano MC.

Evaluation of antibody-dependent cell-mediated cytotoxicity activity and cetuximab response in KRAS wild-type metastatic colorectal cancer patients. World J Gastrointest Oncol. 2016 Feb 15;8(2):222-30. doi: 10.4251/wjgo.v8.i2.222.

testimonial-4

p16 cutoff in head and neck squamous cell carcinoma: correlation between tumor and patient characteristics and outcome.

Merlano MC, Denaro N, Vivenza D, Monteverde M, Russi E, Lerda W, Comino A, Lo Nigro C.

Int J Biol Markers. 2015 Oct 20:0. doi: 10.5301/jbm.5000175. [Epub ahead of print]

testimonial-5

Monteverde M, Milano G, Strola G, Maffi M, Lattanzio L, Vivenza D, Tonissi F, Merlano M, Lo Nigro C.

The relevance of ADCC for EGFR targeting: A review of the literature and a clinically-applicable method of assessment in patients.

Crit Rev Oncol Hematol. 2015 Aug;95(2):179-90. doi: 10.1016/j.critrevonc.2015.02.014. Epub 2015 Mar 12. Review.

testimonial-6

Lattanzio L, Tonissi F, Monteverde M, Vivenza D, Russi E, Milano G, Merlano M, Lo Nigro C.

Treatment effect of buparlisib, cetuximab and irradiation in wild-type or PI3KCA-mutated head and neck cancer cell lines.

Invest New Drugs. 2015 Apr;33(2):310-20. doi: 10.1007/s10637-015-0210-1. Epub 2015 Jan 22.

testimonial-7

Lattanzio L, Borgognone M, Mocellini C, Giordano F, Favata E, Fasano G, Vivenza D, Monteverde M, Tonissi F, Ghiglia A, Fillini C, Bernucci C, Merlano M, Lo Nigro C.

MGMT promoter methylation and glioblastoma: a comparison of analytical methods and of tumor specimens.

Int J Biol Markers. 2015 May 26;30(2):e208-16. doi: 10.5301/jbm.5000126.

testimonial-8

Gaidano G, Capello D, Gloghini A, Fassone L, Vivenza D, Ariatti C, Migliazza A, Saglio G, Carbone A.

Frequent mutation of bcl-6 proto-oncogene in high grade, but not low grade, MALT lymphomas of the gastrointestinal tract. Haematologica. 1999 Jul;84(7):582-8.

testimonial-9

Gaidano G, Vivenza D, Forconi F, Capello D, Gloghini A, Bhatia K, Gutierrez M, Gallicchio M, Avanzi GC, Fassone L, Ariatti C, Buonaiuto D, Cingolani A, Saglio G, Tirelli U, Larocca LM, Dalla-Favera R, Carbone A.

Mutation of BAX occurs infrequently in acquired immunodeficiency syndrome-related non-Hodgkin's lymphomas. Genes Chromosomes Cancer. 2000 Feb;27(2):177-82.

testimonial-10

Capello D, Vitolo U, Pasqualucci L, Quattrone S, Migliaretti G, Fassone L, Ariatti C, Vivenza D, Gloghini A, Pastore C, Lanza C, Nomdedeu J, Botto B, Freilone R, Buonaiuto D, Zagonel V, Gallo E, Palestro G, Saglio G, Dalla-Favera R, Carbone A, Gaidano G.

Distribution and pattern of BCL-6 mutations throughout the spectrum of B-cell neoplasia. Blood. 2000 Jan 15;95(2):651-9.

testimonial-11

Fassone L, Bhatia K, Gutierrez M, Capello D, Gloghini A, Dolcetti R, Vivenza D, Ascoli V, Lo Coco F, Pagani L, Dotti G, Rambaldi A, Raphael M, Tirelli U, Saglio G, Magrath IT, Carbone A, Gaidano G.

Molecular profile of Epstein-Barr virus infection in HHV-8-positive primary effusion lymphoma. Leukemia. 2000 Feb;14(2):271-7.

testimonial-12

Capello D, Gaidano G, Gallicchio M, Gloghini A, Medico E, Vivenza D, Buonaiuto D, Fassone L, Avanzi GC, Saglio G, Prat M, Carbone A.

The tyrosine kinase receptor met and its ligand HGF are co-expressed and functionally active in HHV-8 positive primary effusion lymphoma. Leukemia. 2000 Feb;14(2):285-91.

testimonial-13

Gaidano G, Capello D, Fassone L, Gloghini A, Cilia AM, Ariatti C, Buonaiuto D, Vivenza D, Gallicchio M, Avanzi GC, Prat M, Carbone A.

Molecular characterization of HHV-8 positive primary effusion lymphoma reveals pathogenetic and histogenetic features of the disease. J Clin Virol. 2000 May;16(3):215-24.

testimonial-14

Capello D, Fais F, Vivenza D, Migliaretti G, Chiorazzi N, Gaidano G, Ferrarini M.

Identification of three subgroups of B cell chronic lymphocytic leukemia based upon mutations of BCL-6 and IgV genes. Leukemia. 2000 May;14(5):811-5.

testimonial-15

Ariatti C, Vivenza D, Capello D, Migliazza A, Parvis G, Fassone L, Buonaiuto D, Savinelli F, Rossi D, Saglio G, Gaidano G.

Common-variable immunodeficiency-related lymphomas associate with mutations and rearrangements of BCL-6: pathogenetic and histogenetic implications. Hum Pathol. 2000 Jul;31(7):871-3.

testimonial-16

Fassone L, Gaidano G, Ariatti C, Vivenza D, Capello D, Gloghini A, Cilia AM, Buonaiuto D, Rossi D, Pastore C, Carbone A, Saglio G.

The role of cytokines in the pathogenesis and management of AIDS-related lymphomas. Leuk Lymphoma. 2000 Aug;38(5-6):481-8.

testimonial-17

Ariatti C, Rossi D, Vivenza D, Berra E, Benevolo G, Fontana M, Conconi A.

Molecular characterization of common variable immunodeficiency-related lymphomas. Ann Ital Med Int. 2001 Jul-Sep;16(3):163-9.

testimonial-18

Fassone L, Cingolani A, Martini M, Migliaretti G, Oreste PL, Capello D, Gloghini A, Vivenza D, Dolcetti R, Carbone A, Antinori A, Gaidano G, Larocca LM.

Characterization of Epstein-Barr virus genotype in AIDS-related non-Hodgkin's lymphoma. AIDS Res Hum Retroviruses. 2002 Jan 1;18(1):19-26.

testimonial-19

Vitolo U, Botto B, Capello D, Vivenza D, Zagonel V, Gloghini A, Novero D, Parvis G, Calvi R, Ariatti C, Milan I, Bertini M, Boccomini C, Freilone R, Pregno P, Orsucci L, Palestro G, Saglio G, Carbone A, Gallo E, Gaidano G.

Point mutations of the BCL-6 gene: clinical and prognostic correlation in B-diffuse large cell lymphoma. Leukemia. 2002 Feb;16(2):268-75.

testimonial-20

Buonaiuto D, Rossi D, Guidetti F, Vivenza D, Berra E, Deambrogi C, Ariatti C, Franceschetti S, Conconi A, Ronco M, Valente G, Colombi S.

Human herpesvirus type 8-associated primary lymphomatous effusion in an elderly HIV-negative patient:clinical and molecular characterization. Ann Ital Med Int. 2002 Jan-Mar;17(1):54-9.

testimonial-21

Bellone S, Rapa A, Vivenza D, Castellino N, Petri A, Bellone J, Me E, Broglio F, Prodam F, Ghigo E, Bona G.

Circulating ghrelin levels as function of gender, pubertal status and adiposity in childhood. J Endocrinol Invest. 2002 May;25(5):RC13-5.

testimonial-22

Pileri SA, Sabattini E, Rosito P, Zinzani PL, Ascani S, Fraternali-Orcioni G, Gamberi B, Piccioli M, Vivenza D, Falini B, Gaidano G.

Primary follicular lymphoma of the testis in childhood: an entity with peculiar clinical and molecular characteristics. J Clin Pathol. 2002 Sep;55(9):684-8.

testimonial-23

Paulli M, Viglio A, Vivenza D, Capello D, Rossi D, Riboni R, Lucioni M, Incardona P, Boveri E, Bellosta M, Orlandi E, Borroni G, Lazzarino M, Berti E, Alessi E, Magrini U, Gaidano G.

Primary cutaneous large B-cell lymphoma of the leg: histogenetic analysis of a controversial clinicopathologic entity. Hum Pathol. 2002 Sep;33(9):937-43.

testimonial-24

Bellone S, Rapa A, Vivenza D, Vercellotti A, Petri A, Radetti G, Bellone J, Broglio F, Ghigo E, Bona G.

Circulating ghrelin levels in newborns are not associated to gender, body weight and hormonal parameters but depend on the type of delivery. J Endocrinol Invest. 2003 Apr;26(4):RC9-11.

testimonial-25

Gottero C, Bellone S, Rapa A, van Koetsveld P, Vivenza D, Prodam F, Benso A,  Destefanis S, Gauna C, Bellone J, Hofland L, van der Lely AJ, Bona G, Ghigo E, Broglio F.

Standard light breakfast inhibits circulating ghrelin level to the same extent of oral glucose load in humans, despite different impact on glucose and insulin levels. J Endocrinol Invest. 2003 Dec;26(12):1203-7.

testimonial-26

Bellone S, Castellino N, Broglio F, Rapa A, Vivenza D, Radetti G, Bellone J,  Gottero C, Ghigo E, Bona G.

Ghrelin secretion in childhood is refractory to the inhibitory effect of feeding. J Clin Endocrinol Metab. 2004 Apr;89(4):1662-5.

testimonial-27

Bellone S, Rapa A, Vivenza D, Vercellotti A, Petri A, Radetti G, Bellone J, Broglio F, Ghigo E, Bona G.

Circulating ghrelin levels in the newborn are positively associated with gestational age. Clin Endocrinol (Oxf). 2004 May;60(5):613-7.

testimonial-28

Vivenza D, Rapa A, Castellino N, Bellone S, Petri A, Vacca G, Aimaretti G, Broglio F, Bona G.

Ghrelin gene polymorphisms and ghrelin, insulin, IGF-I, leptin and anthropometric data in children and adolescents. Eur J Endocrinol. 2004 Jul;151(1):127-33.

testimonial-29

Broglio F, Gottero C, Prodam F, Destefanis S, Gauna C, Me E, Riganti F, Vivenza D, Rapa A, Martina V, Arvat E, Bona G, van der Lely AJ, Ghigo E.

 Ghrelin  secretion is inhibited by glucose load and insulin-induced hypoglycaemia but unaffected by glucagon and arginine in humans. Clin Endocrinol (Oxf). 2004 Oct;61(4):503-9.

testimonial-30

Vivenza D, Guazzarotti L, Godi M, Frasca D, di Natale B, Momigliano-Richiardi P, Bona G, Giordano M.

 A novel deletion in the GH1 gene including the IVS3 branch site responsible for autosomal dominant isolated growth hormone deficiency. J Clin Endocrinol Metab. 2006 Mar;91(3):980-6. Epub 2005 Dec 20.

testimonial-31

Baldelli R, Bellone S, Castellino N, Petri A, Rapa A, Vivenza D, Bellone J, Broglio F, Ghigo E, Bona G.

Oral glucose load inhibits circulating ghrelin levels to the same extent in normal and obese children. Clin Endocrinol (Oxf). 2006 Mar;64(3):255-9. IF =

testimonial-32

Bellone S, Baldelli R, Radetti G, Rapa A, Vivenza D, Petri A, Savastio S, Zaffaroni M, Broglio F, Ghigo E, Bona G.

Ghrelin secretion in preterm neonates progressively increases and is refractory to the inhibitory effect of food intake. J Clin Endocrinol Metab. 2006 May;91(5):1929-33. Epub 2006 Mar 7.

testimonial-33

Arrigo T, Wasniewska M, De Luca F, Valenzise M, Lombardo F, Vivenza D, Vaccaro T, Coradi E, Biason-Lauber A.

Congenital adenohypophysis aplasia: clinical features and analysis of the transcriptional factors for embryonic pituitary development. J Endocrinol Invest. 2006 Mar;29(3):208-13.

testimonial-34

Oderda G, Vivenza D, Rapa A, Boldorini R, Bonsignori I, Bona G.

Increased interleukin-10 in Helicobacter pylori infection could be involved in the mechanism protecting from allergy. J Pediatr Gastroenterol Nutr. 2007 Sep;45(3):301-5.

testimonial-35

Bona G, Corneli G, Vivenza D, Bellone S, Prodam F, Godi M, Giordano M, Momigliano P.

[Genetics of low stature]. Minerva Pediatr. 2007 Oct;59(5):543-4.

testimonial-36

Giordano M, Godi M, Mellone S, Petri A, Vivenza D, Tiradani L, Carlomagno Y, Ferrante D, Arrigo T, Corneli G, Bellone S, Giacopelli F, Santoro C, Bona G, Momigliano-Richiardi P.

A functional common polymorphism in the vitamin D-responsive element of the GH1 promoter contributes to isolated growth hormone deficiency. J Clin Endocrinol Metab. 2008 Mar;93(3):1005-12. Epub 2007 Dec 26.

testimonial-37

Corneli G, Vivenza D, Prodam F, Di Dio G, Vottero A, Rapa A, Bellone S, Bernasconi S, Bona G.

Heterozygous mutation of HESX1 causing hypopituitarism and multiple anatomical malformations without features of septo-optic dysplasia. J Endocrinol Invest. 2008 Aug;31(8):689-93.

testimonial-38

Caristo E, Parola A, Rapa A, Vivenza D, Raselli B, Dondi E, Boldorini R, Oderda G.

Clarithromycin resistance of Helicobacter pylori strains isolated from children' gastric antrum and fundus as assessed by fluorescent in-situ hybridization and culture on four-sector agar plates. Helicobacter. 2008 Dec;13(6):557-63. doi: 10.1111/j.1523-5378.2008.00642.x. IF =

testimonial-39

Balossini V, Monzani A, Rapa A, Vivenza D, Caristo E, Oderda G.

Interleukin-10 and transforming growth factor-beta1 in cord blood: relationship with paternal allergy and cesarean section. Acta Paediatr. 2009 May;98(5):812-6. doi: 10.1111/j.1651-2227.2008.01194.x. Epub 2009 Jan 13.

testimonial-40

Rapa A, Monzani A, Moia S, Vivenza D, Bellone S, Petri A, Teofoli F, Cassio A, Cesaretti G, Corrias A, de Sanctis V, Di Maio S, Volta C, Wasniewska M, Tatò L, Bona G.

Subclinical hypothyroidism in children and adolescents: a wide range of clinical, biochemical, and genetic factors involved. J Clin Endocrinol Metab. 2009 Jul;94(7):2414-20. doi: 10.1210/jc.2009-0375. Epub 2009 May 5.

testimonial-41

Carlomagno Y, Salerno M, Vivenza D, Capalbo D, Godi M, Mellone S, Tiradani L, Corneli G, Momigliano-Richiardi P, Bona G, Giordano M.

A novel recessive splicing mutation in the POU1F1 gene causing combined pituitary hormone deficiency. J Endocrinol Invest. 2009 Sep;32(8):653-8. doi: 10.3275/6278. Epub 2009 May 12.

testimonial-42

Vivenza D, Godi M, Faienza MF, Mellone S, Moia S, Rapa A, Petri A, Bellone S,  Riccomagno S, Cavallo L, Giordano M, Bona G.

A novel HESX1 splice mutation causes isolated GH deficiency by interfering with mRNA processing. Eur J Endocrinol. 2011 May;164(5):705-13. doi: 10.1530/EJE-11-0047. Epub 2011 Feb 16.

testimonial-43

Lo Nigro C, Vivenza D, Monteverde M, Lattanzio L, Gojis O, Garrone O, Comino A, Merlano M, Quinlan PR, Syed N, Purdie CA, Thompson A, Palmieri C, Crook T.

 High frequency of complex TP53 mutations in CNS metastases from breast cancer. Br J Cancer. 2012 Jan 17;106(2):397-404. doi: 10.1038/bjc.2011.464. Epub 2011 Dec 20.

testimonial-44

Garrone O, Crosetto N, Lo Nigro C, Catzeddu T, Vivenza D, Monteverde M, Merlano M, Feola M.

 Prediction of anthracycline cardiotoxicity after chemotherapy by biomarkers kinetic analysis. Cardiovasc Toxicol. 2012 Jun;12(2):135-42. doi:10.1007/s12012-011-9149-4.

testimonial-45

Vivenza D, Gasco M, Monteverde M, Lattanzio L, Syed N, Colantonio I, Denaro N, Natoli G, Comino A, Russi E, Merlano M, Crook T, Lo Nigro C.

MDM2 309 polymorphism predicts outcome in platinum-treated locally advanced head and neck cancer. Oral Oncol. 2012 Jul;48(7):602-7. doi:10.1016/j.oraloncology.2012.01.022. Epub 2012 Feb 21.

testimonial-46

Lo Nigro C, Monteverde M, Lee S, Lattanzio L, Vivenza D, Comino A, Syed N, McHugh A, Wang H, Proby C, Garrone O, Merlano M, Hatzimichael E, Briasoulis E, Gojis O, Palmieri C, Jordan L, Quinlan P, Thompson A, Crook T.

 NT5E CpG island methylation is a favourable breast cancer biomarker. Br J Cancer. 2012 Jun26;107(1):75-83. doi: 10.1038/bjc.2012.212. Epub 2012 May 31.

testimonial-47

Hatzimichael E, Lo Nigro C, Lattanzio L, Syed N, Shah R, Dasoula A, Janczar K,Vivenza D, Monteverde M, Merlano M, Papoudou-Bai A, Bai M, Schmid P, Stebbing J, Bower M, Dyer MJ, Karran LE, ElguetaKarstegl C, Farrell PJ, Thompson A,Briasoulis E, Crook T.

The collagen prolyl hydroxylases are novel transcriptionally silenced genes in lymphoma. Br J Cancer. 2012 Oct 9;107(8):1423-32. doi: 10.1038/bjc.2012.380. Epub 2012 Sep 6.

testimonial-48

Vivenza D, Feola M, Garrone O, Monteverde M, Merlano M, Lo Nigro C.

Role of the renin-angiotensin-aldosterone system and the glutathione S-transferase Mu, Pi and Theta gene polymorphisms in cardiotoxicity after anthracycline chemotherapy for breast carcinoma. Int J Biol Markers. 2013 Aug 30:0. doi: 10.5301/jbm.5000041.

Timetable

There is no event available.

Ask a Question

Contact Info